newsfilter
← Latest News
Business Wire·

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Incyte (NASDAQ:INCY) and Genmab A/S (NASDAQ:GMAB) today